Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Evaluation of CONTOUR® USB BGMS on Glycaemic Control in Insulin-treated Diabetic Patients (CONGO)

This study has been completed.
Information provided by (Responsible Party):
GWT-TUD GmbH Identifier:
First received: April 26, 2012
Last updated: January 19, 2017
Last verified: January 2016

The purpose of this study is to evaluate if the use of the CONTOUR Next USB BGMS system with AutoLog and Trends features and integrated data management software (Glucofacts ™ DELUXE) enables behavioral changes that may lead to improvement in glycemic control, expressed as a reduction in HbA1c as primary endpoint.

Patients will be randomized either to using CONTOUR Next USB or CONTOUR. Patients will be trained in using the devices and return every 3 months until month 9 after baseline.

Diabetes Mellitus Type 2

Study Type: Observational
Study Design: Observational Model: Case-Control
Time Perspective: Prospective
Official Title: Evaluation of the Impact of the CONTOUR® USB Blood Glucose Monitoring System With Integrated Data Management on Glycaemic Control in Insulin-treated Diabetic Patients

Further study details as provided by GWT-TUD GmbH:

Primary Outcome Measures:
  • Reduction in HbA1c [ Time Frame: Baseline, after 9 months ]

Enrollment: 154
Study Start Date: June 2012
Study Completion Date: January 2016
Primary Completion Date: October 2015 (Final data collection date for primary outcome measure)
Test group
patients using CONTOUR Next USB
Control group
patients using standard CONTOUR


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
patients of assorted practices

Inclusion Criteria:

  • Type 2 diabetes
  • Therapy with insulin only (ICT) or ICT in combination with Metformin
  • HbA1c at baseline > 7.5% and < 11%
  • Patients at least 18 years of age
  • Patients willing to complete all study visits and study procedures including:

    • Testing their BG at least 3 times a day during the entire study.
    • Using the paper logbook provided (control group)
    • Using the Auto log meal-marker + reminder feature in CONTOUR Next USB regularly (TEST subjects only)
    • Using the Trends feature in CONTOUR Next USB regularly (TEST subjects only)
    • Uploading the CONTOUR Next USB meter to personal computer (subject must have personal computer at home or access to a computer - see system requirements in appendix for technical details).
  • Patients who are able to speak, read and understand German
  • Patients who are currently performing self-testing of blood glucose at home routinely (at least 3 times per day) for 4 weeks or more
  • Patients who are currently adjusting there insulin dosages themselves based on the self-testing of blood glucose at home
  • Written informed consent at beginning of the study

Exclusion Criteria:

  • Patients who have been using CONTOUR Next USB meter regularly during the previous 12 months
  • Patients treated with oral antidiabetic drugs except for Metformin; or diet alone
  • Change of diabetes therapy within the last 3 months
  • Change of HbA1c level of more than ±0.5% within the last 3 months
  • Patients who are using a continuous blood glucose measurement system regularly
  • Patients with home health aides who assist with their BG testing and /or insulin adjustment
  • Patients with macroalbuminuria
  • Steroid therapy within the last 3 months. Topic or inhalative use is no exclusion criterion when not used regularly (more than 5 times a week).
  • Uncontrolled blood pressure ≥ 170/100 at screening
  • BMI > 40 kg/m²
  • Anemia according to WHO-definition (hemoglobin < 13 g/100 ml [male] or < 12 g/100 ml [female])
  • Creatinin > 150 µmol/l and/or GFR < 50 mmol/min/ 1.73m² (measured within the last 3 months before screening)
  • Operation with inpatient stay planned during the study
  • Current pregnancy or pregnancy planned during the study; or breastfeeding women.
  • Women with childbearing potential who are not practicing an acceptable method of birth control. Acceptable methods of birth control include tubal ligation, transdermal patch, intra uterine devices/systems (IUDs/IUSs), oral, implantable or injectable contraceptives, sexual abstinence, double barrier method and vasectomized partner
  • Alcohol or drug abuse within the last 3 months
  • Patients with the following impairments which, in the opinion of the investigator, would seriously compromise the integrity of the study:

    • Significant visual impairment
    • Significant hearing impairment
    • Cognitive disorder
    • Significant unstable co-morbidity (with notable change within the past 3 months)
    • Severe renal disease, disease with a strong impact on life expectancy
    • Inability to have or use and computer
    • Inability to use a meter correctly
    • Any other condition as per investigator's discretion
  • Current participation in another clinical study. Participation in another trial within 6 weeks before screening.
  • Employees of Bayer Vital Diabetes Care, the GWT or the University of Dresden
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01588106

Diabetespraxis Prenzlauer Allee
Berlin, Germany, 10409
Praxis Dr. Fießelmann
Berlin, Germany, 13597
Praxis Dr. Stephan
Berlin, Germany, 13597
Gemeinschaftspraxis Lorra/Bonnermann
Bochum, Germany, 44869
Praxis Dr. Holderied
Brand-Erbisdorf, Germany, 09618
Burg, Germany, 03096
Diabeteszentrum DO
Dortmund, Germany, 44137
Studienzentrum Prof. Hanefeld
Dresden, Germany, 01307
Universitätsklinikum Dresden, Medizinische Klinik III
Dresden, Germany, 01307
Gemeinschaftspraxis Schaden
Düsseldorf, Germany, 40211
Praxis Dr. Stier
Freital, Germany, 01705
Magdeburg, Germany, 39112
Praxis Dr. Ruhland
München, Germany, 80331
München, Germany, 80687
Praxis Dr. Engelmayer
München, Germany, 81241
Diabeteszentrum Oschatz
Oschatz, Germany, 04758
Sponsors and Collaborators
Principal Investigator: Peter Schwarz, Prof Universitätsklinikum Carl Gustav Carus
  More Information

Responsible Party: GWT-TUD GmbH Identifier: NCT01588106     History of Changes
Other Study ID Numbers: GWT-2011-1
Study First Received: April 26, 2012
Results First Received: January 19, 2017
Last Updated: January 19, 2017

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases processed this record on April 28, 2017